Literature DB >> 12074364

Oligonucleotide conjugates as potential antisense drugs with improved uptake, biodistribution, targeted delivery, and mechanism of action.

Muthiah Manoharan1.   

Abstract

This review summarizes the effect of conjugating small molecules and large biomacromolecules to antisense oligonucleotides to improve their therapeutic potential. In many cases, favorable changes in pharmacokinetic and pharmacodynamic properties were observed. Opportunities exist to change the terminating mechanism of antisense action or to enhance the RNase H mode of action via conjugate formation.

Entities:  

Mesh：

Substances：

Year:  2002        PMID： 12074364     DOI： 10.1089/108729002760070849

Source DB:  PubMed          Journal:  Antisense Nucleic Acid Drug Dev        ISSN： 1087-2906


  28 in total

1.  Coordinate inhibition of expression of several genes for protein subunits of human nuclear RNase P.

Authors:  Elizaveta Kovrigina; Donna Wesolowski; Sidney Altman
Journal:  Proc Natl Acad Sci U S A       Date:  2003-01-27       Impact factor: 11.205

2.  Improved delivery in cell culture of radiolabeled antisense DNAs by duplex formation.

Authors:  Xinrong Liu; Kayoko Nakamura; Yi Wang; Surong Zhang; Jiang He; Guozheng Liu; Shuping Dou; Atsushi Kubo; Mary Rusckowski; Donald Hnatowich
Journal:  Mol Imaging Biol       Date:  2006 Sep-Oct       Impact factor: 3.488

Review 3.  Chemical modification: the key to clinical application of RNA interference?

Authors:  David R Corey
Journal:  J Clin Invest       Date:  2007-12       Impact factor: 14.808

4.  Radiolabeled oligonucleotides for antisense imaging.

Authors:  Arun K Iyer; Jiang He
Journal:  Curr Org Synth       Date:  2011-08-01       Impact factor: 1.975

5.  Nucleic acid-based nanoengineering: novel structures for biomedical applications.

Authors:  Hanying Li; Thomas H Labean; Kam W Leong
Journal:  Interface Focus       Date:  2011-06-28       Impact factor: 3.906

6.  Tat-conjugated PAMAM dendrimers as delivery agents for antisense and siRNA oligonucleotides.

Authors:  Hyunmin Kang; Robert DeLong; Michael H Fisher; Rudolph L Juliano
Journal:  Pharm Res       Date:  2005-10-01       Impact factor: 4.200

7.  The pharmacology of HIV drug resistance.

Authors:  Martin M Zdanowicz
Journal:  Am J Pharm Educ       Date:  2006-10-15       Impact factor: 2.047

8.  Novel antisense oligonucleotides containing hydroxamate linkages: targeted iron-triggered chemical nucleases.

Authors:  Marvin J Miller; Hui Li; Catherine A Foss
Journal:  Biometals       Date:  2009-01-28       Impact factor: 2.949

9.  Influence of two transfectors on delivery of 99mTc antisense DNA in tumor-bearing mice.

Authors:  Kayoko Nakamura; Yi Wang; Xinrong Liu; Atsushi Kubo; Donald J Hnatowich
Journal:  Mol Imaging Biol       Date:  2006 May-Jun       Impact factor: 3.488

10.  Novel Targeted Therapy for Precursor B Cell Acute Lymphoblastic Leukemia: anti-CD22 Antibody-MXD3 Antisense Oligonucleotide Conjugate.

Authors:  Noriko Satake; Connie Duong; Sakiko Yoshida; Michael Oestergaard; Cathy Chen; Rachael Peralta; Shuling Guo; Punit P Seth; Yueju Li; Laurel Beckett; Jong Chung; Jan Nolta; Nitin Nitin; Joseph M Tuscano
Journal:  Mol Med       Date:  2016-07-22       Impact factor: 6.354
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.